Palisade Bio (PALI) Conference June 17, 2024 08:30 AM ET Speaker0 Okay. We are ready to get started. Good afternoon, and welcome back to the Virtual Investor twenty twenty four Pitch Conference. My name is Janine Thomas. I am CEO of JTCIR, and I will be the moderator for today's event. So for this event, each presenting company will provide a five to seven minute elevator pitch followed by a q and a session. We had a great morning session. And to kick off our afternoon session, I am pleased to be joined by ...

A downtrend has been apparent in Palisade Bio, Inc. (PALI) lately. While the stock has lost 29.7% over the past four weeks, it could witness a trend reversal as a hammer chart pattern was formed in its last trading session. This could mean that the bulls have been able to counteract the bears to help the stock find support. The formation of a hammer pattern is considered a technical indication of nearing a bottom with likely subsiding of selling pressure. But this is not the only factor that makes a bullish ...

Carlsbad, CA, June 11, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for patent application number 3,174,137 titled, "Gut Microbiota Bioactivated PDE4 Inhibitor Precursors." This patent covers the composition o ...

As part of the event, J.D. Finley, Chief Executive Officer of Palisade Bio, will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed. Palisade Bio is a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and ...

As part of the event, J.D. Finley, Chief Executive Officer of Palisade Bio, will provide an "elevator pitch" and outline the Company's upcoming milestones. Additionally, investors and interested parties will have the opportunity to submit questions live during the event. Participating companies will answer as many questions as possible in the time allowed. About Palisade Bio Carlsbad, CA, June 10, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) ("Palisade" or the "Company"), biopharmaceutical com ...

Data presented at Digestive Disease Week (DDW) 2024 Preclinical data demonstrate PALI-2108 to be safe, effective, and well tolerated PALI-2108 is orally delivered and colon-specific allowing for local activity with low systemic exposure Carlsbad, CA, May 21, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade" or the "Company"), biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today ann ...

The poster titled, "Local Bioactivation and efficacy of PALI-2108: A Promising PDE4 Inhibitor Prodrug for Ulcerative Colitis Treatment," is being presented by Dr. Mitch Jones as part of the Animal Models of IBD: Pre- Clinical Treatment of Intestinal Inflammation session being held today, May 21, 2024. The poster is available on the Scientific Publications page of the Company's website. "The findings from this preclinical study add to our growing body of encouraging data for PALI-2108 and further bolster our ...

Carlsbad, CA, May 14, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (NASDAQ:PALI) ("Palisade", "Palisade Bio" or the "Company"), a biopharmaceutical company focused on developing and advancing novel therapeutics for patients living with autoimmune, inflammatory, and fibrotic diseases, today reported its financial results for the first quarter 2024 and provided a business update. Recent Highlights "Our team remains focused on advancing PALI-2108 towards our first-in-human study, which is on track to start late ...

(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q For the transition period from to Commission File Number: 001-33672 PALISADE BIO, INC. (Exact name of registrant as specified in its charter) Delaware 52-2007292 (State or other jurisdictio ...

NASDAQ: PALI | palisadebio.com 100 Protecting Intestinal Barrier Health July 2022 Corporate Presentation Forward Looking Statements Statements in this presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding our research and clinical development plans, expected near-term Phase 2 and Phase 3 milestones (including but not limited to, enrollment completion), hypothesis leading to adhesion formation, ...